Marker Therapeutics Management
Management criteria checks 2/4
Marker Therapeutics' CEO is Juan Vera, appointed in May 2023, has a tenure of 1.58 years. total yearly compensation is $585.25K, comprised of 68.2% salary and 31.8% bonuses, including company stock and options. directly owns 2.99% of the company’s shares, worth €868.67K. The average tenure of the management team and the board of directors is 1.6 years and 6.4 years respectively.
Key information
Juan Vera
Chief executive officer
US$585.3k
Total compensation
| CEO salary percentage | 68.2% |
| CEO tenure | 1.6yrs |
| CEO ownership | 3.0% |
| Management average tenure | 1.6yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$10m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$12m |
| Dec 31 2023 | US$585k | US$399k | -US$14m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$582k | US$380k | -US$20m |
Compensation vs Market: Juan's total compensation ($USD585.25K) is about average for companies of similar size in the German market ($USD468.04K).
Compensation vs Earnings: Juan's compensation has increased whilst the company is unprofitable.
CEO
Juan Vera (44 yo)
1.6yrs
Tenure
US$585,251
Compensation
Dr. Juan F. Vera, MD, serves as Chief Executive Officer and President at Marker Therapeutics, Inc. since May 1, 2023 and serves as its Secretary and Treasurer. He has held various positions at the Center f...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 1.6yrs | US$585.25k | 2.99% € 868.7k | |
| Director of Administration | 8.3yrs | no data | no data | |
| Director of Corporate Operations & External Communications | less than a year | no data | no data | |
| Vice President of Human Resources | 1.9yrs | no data | no data | |
| Chief Medical Officer | 1.6yrs | no data | no data | |
| Head of Clinical Operations | less than a year | no data | no data | |
| Head of Regulatory Affairs | less than a year | no data | no data | |
| Senior Director of Molecular Biology & Virology | no data | no data | no data |
1.6yrs
Average Tenure
44yo
Average Age
Experienced Management: GX1's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.2yrs | US$585.25k | 2.99% € 868.7k | |
| Independent Director | 5.3yrs | US$76.14k | 0.033% € 9.6k | |
| Member of Scientific Advisory Board | 6.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.9yrs | no data | no data | |
| Independent Chairman | 6.2yrs | US$124.04k | 0.041% € 12.0k | |
| Member of Scientific Advisory Board | 6.6yrs | no data | no data | |
| Independent Director | 6.2yrs | US$63.44k | 8.75% € 2.5m | |
| Member of Scientific Advisory Board | 6.9yrs | no data | no data | |
| Independent Director | 3yrs | US$79.67k | 0.0017% € 487.4 |
6.4yrs
Average Tenure
62yo
Average Age
Experienced Board: GX1's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 03:31 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Marker Therapeutics, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Yun Zhong | Janney Montgomery Scott LLC |
| Aydin Huseynov | Ladenburg Thalmann & Company |